Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. ASML
2. USO
3. LAD
4. ROIV
5. DKNG
6. BSX
7. ODFL
8. NVS
9. AHR
10. ALV

Go back to Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
ALKERMES (NASDAQ: ALKS) Delayed: 46.10 --0 (-0%)
Previous Close $46.10    52 Week High $80.71 
Open $46.10    52 Week Low $27.14 
Day High $46.10    P/E 354.62 
Day Low $46.10    EPS $0.13 
Volume 56